The combination of brentuximab vedotin and ibrutinib was well-tolerated and resulted in an overall response rate of 69%, a complete response rate of 46%, and a disease control rate of 100% in patients with relapsed/refractory Hodgkin lymphoma.
In patients with relapsed/refractory, aggressive non-Hodgkin lymphoma (NHL), use of prophylactic tocilizumab may reduce the incidence of severe cytokine release syndrome but not neurologic events in patients treated with chimeric antigen receptor T-cell therapy.
In a pooled analysis of 370 patients with relapsed/refractory mantle-cell lymphoma, treatment with ibrutinib for a median follow-up of 3.5 years resulted in 26% being progression-free and 45% still alive, with manageable toxicity.
In a retrospective cohort analysis of the largest series of patients with mantle-cell lymphoma (MCL) in which real-world economic burden data have been reported, the substantial economic burden of MCL was quantified, with inpatient admissions and office visits as the largest drivers of total costs for patients treated with rituximab, cyclophosphamide, doxorubicin, and vincristine; bendamustine and rituximab; and rituximab, and prescription drug costs as the largest component of total costs for patients receiving ibrutinib.
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab used as first-line treatment in patients with chronic lymphocytic leukemia (CLL) with mutated IGHV achieves a high rate of undetectable minimal residual disease and complete remission after 3 courses, with an acceptable safety profile.